Business Context and Reporting Period
This Form 8-K is a Current Report filed by Semper Paratus Acquisition Corporation (not Tevogen Inc.) on January 26, 2023. The filing serves as an Amendment and Supplement to a Definitive Proxy Statement filed on January 20, 2023. The Company is a Cayman Islands-based Special Purpose Acquisition Company (SPAC) seeking shareholder approval to extend the deadline to complete an initial business combination. The filing corrects typographical errors regarding the amount held in the Trust Account.
Key Financial Metrics
- Trust Account Balance (as of Dec 31, 2022): Approximately $256,356.86 million (Note: The text contains a likely typographical error in the magnitude; context suggests this figure may be intended as $256,356.86 or similar, but the text explicitly states "$256 356.86 million").
- Trust Account Balance (as of Sept 30, 2022): Basis for a liquidation value of approximately $10.20 per share.
- Projected Liquidation Value (as of Dec 31, 2022): Approximately $10.34 per share.
- Warrant Exercise Price: $11.50 per share.
- Revenue/Profit/Cash Flow: The filing does not provide operating revenue, profit, or cash flow metrics as the Company is a pre-business combination SPAC.
Material Changes and Corrections
The filing amends the Definitive Proxy Statement to correct disclosures regarding the Trust Account balance and the potential impact of the proposed Extension on shareholder equity:
- Trust Account Reduction: If the Extension is approved, the removal of the "Withdrawal Amount" will reduce the Trust Account balance. The remaining amount could be a small fraction of the balance as of the Record Date.
- Dilution Impact: The reduction in the Trust Account will increase the percentage interest in Ordinary Shares held by initial shareholders, directors, and officers.
- Liquidation Value Correction: The filing updates the estimated liquidation distribution to public shareholders from $10.20 per share (based on Sept 30, 2022 data) to approximately $10.34 per share (based on Dec 31, 2022 data).
Outlook, Risks, and Management Commentary
- Extension Proposal: Shareholders will vote on February 3, 2023, to extend the time period to complete a Business Combination.
- Funding Risk: If the Trust Account balance is significantly reduced, the Company may need to obtain additional funds to complete a Business Combination. There is no assurance such funds will be available.
- Liquidation Risk: If the Company fails to complete a Business Combination within the required time, it must liquidate. In this scenario, public shareholders may receive approximately $10.34 per share, and warrants will expire worthless.
- Regulatory Risk: If the Company is deemed subject to the Investment Company Act, compliance costs could hinder the Business Combination, potentially leading to liquidation.
- Forward-Looking Statements: Management notes that actual results may differ materially from projections due to various risks outlined in the Definitive Proxy Statement.
Key Facts for Investor Verification
- Verify the exact magnitude of the Trust Account balance ($256,356.86 million vs. likely $256,356.86) in the original Definitive Proxy Statement to confirm the typo correction.
- Confirm the specific amount of the "Withdrawal Amount" to be removed from the Trust Account upon Extension approval.
- Review the Definitive Proxy Statement for the full list of participants in the proxy solicitation and their interests.
- Monitor the outcome of the Extraordinary General Meeting scheduled for February 3, 2023.
- Assess the risk of warrant expiration if the Company is forced to liquidate.